The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: John Young - Canaccord Genuity - Analyst
: Hey, Jim. Thanks for taking the question. Congrats on the quarter. I just want to start on NanoKnife and just the comments around the CPT pathway.
Will you launch the -- can you provide initially this timeline for that beyond the October date from the Editorial committee? And then would you
launch that the without commercializing without the code initially?
And then also, how are you going to think about the price? If you do get a Level 1 CPT code, would you price the disposal for the prostate higher
than just the other disposables currently? Any premium you could take there? Thanks.
Question: John Young - Canaccord Genuity - Analyst
: Okay. Great. Thanks for the color. And just the cash burn in this quarter. It was pretty significant, $21 million, I believe. Can you just walk us through
just your ability to take cash flow breakeven? I know you had targeted previously on profitability in fiscal year '26. Do you still expect that and just
that pathway to cash flow positivity. Thank you.
Question: John Young - Canaccord Genuity - Analyst
: Maybe I could just use one more in here, too. Just on the med device. So the comments on the OUS order timing, should we expect some of the
revenue to be pushed out [F 2Q]?
Question: John Young - Canaccord Genuity - Analyst
: Great. Thank you again.
Question: Yi Chen - H.C. Wainwright & Co., LLC - Analyst
: Thank you for taking my questions. Could you give us some additional color your expected launch trajectory for Auryon in Europe? And roughly
what time frame for Europe, do you expect the Auryon achieve the kind of similar level of sales in the US. Thank you.
Question: Yi Chen - H.C. Wainwright & Co., LLC - Analyst
: Got it. And with respect to the issue due to the timing of international orders, has the issue been resolved? And has it only affected sales of NanoKnife?
Question: Yi Chen - H.C. Wainwright & Co., LLC - Analyst
: So just to clarify the timing issue could recur in the future, correct?
Question: Yi Chen - H.C. Wainwright & Co., LLC - Analyst
: Got it. Thank you.
| 
